Pfizer Receives Authorization from Health Authority for the First Dual Indication Vaccine Approved in Hong Kong
PR Newswire Asia
*A Vaccine to Fight Against Respiratory Syncytial Virus (RSV) in Older Adults Aged 60 and Above and Infants (Through Maternal..